75 results
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
9 May 24
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
4:17pm
biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing … an innovative immuno-oncology pipeline that is expected to be synergistic with its proven commercial capabilities in oncology.
Coherus’ immuno-oncology
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
13 Mar 24
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
4:16pm
and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline that will be synergistic with its
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
4 Mar 24
Completion of Acquisition or Disposition of Assets
6:22am
of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline of tumor microenvironment agents
8-K
EX-99.1
7qeyzfjdl3p grm
5 Feb 24
Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP
8:09am
8-K
EX-99.1
t0zk7w5hl36qgc1mygj
22 Jan 24
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in Conference Call Information
8:01am
8-K
EX-99.1
ijgztd0ve1
6 Nov 23
Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
4:31pm
8-K
EX-99.1
n0t9cb 6h00dpsky
27 Oct 23
Regulation FD Disclosure
4:19pm
424B5
dpamo 9yyqo14c
12 Sep 23
Prospectus supplement for primary offering
6:04am
8-K
EX-99.1
t0joso5s7vqe y5pyq6z
8 Sep 23
Coherus Completes Surface Oncology Acquisition
9:12am
8-K
EX-99.1
q8gr6lvvo xgusyo
2 Aug 23
Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights
4:05pm
424B3
rfmim
26 Jul 23
Prospectus supplement
4:59pm
S-4/A
o89dh1w wt2
24 Jul 23
Registration of securities issued in business combination transactions (amended)
4:42pm
S-4
qyjr1mhhcfv e52uba
7 Jul 23
Registration of securities issued in business combination transactions
5:03pm
425
qk7ahe2jm8y9k
16 Jun 23
Business combination disclosure
5:14pm
425
g6g5zb7h ihmm5cw
16 Jun 23
Business combination disclosure
5:12pm
425
x28 hdawcd
16 Jun 23
Business combination disclosure
5:11pm